Global Gastrointestinal Stromal Tumors Market Research Report: By Indication (Stomach, Small Intestine, Other Indication), Diagnosis (Endoscopic Ultrasound, Biopsy, Others), Treatment (Surgery, Targeted Therapy), and End-User– Global Forecast Till 2023
The Global Gastrointestinal Stromal Tumors Market is expected to gain prominence over the forecast period (2018–2023). It is estimated that the global gastrointestinal stromal tumors market is expected to register at a CAGR ~ 7 % during the forecast period of 2018–2023.
A Gastrointestinal Stromal Tumor (GIST) is a type of tumor which occurs in the gastrointestinal tract and most commonly in the stomach or small intestine. These tumors grow from specialized cells found in the gastrointestinal tract called Interstitial Cells of Cajal (ICC) or precursors to these cells. GIST affects an estimated 11 to 20 patients per million per year worldwide.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/1583
GISTs are rare cancers known as soft tissue sarcomas. These tissue sarcomas develop in supporting and connective tissues. These GIST accounts for around 20% of soft tissue sarcomas and is the most common mesenchymal tumors affecting the gastrointestinal tract. Treatment of GIST is largely dependent on the size of the tumor, position, and development rate, and is most commonly removed through the procedure of surgical resection and targeted therapies.
The growth of this market is due to increasing prevalence of gastrointestinal diseases, increasing the prevalence of cancer, increasing investments and funding in the field of life science research, increasing awareness among the people, growing geriatric population, changing reimbursement policies and various others.
However, one of the major factors that hampered the growth of the gastrointestinal stromal tumors is the presence of misbranded and spurious drugs.
- Bayer AG (Germany)
- Novartis AG (Switzerland),
- Immunicum AB (Sweden),
- F. Hoffmann-La Roche Ltd.(Switzerland),
- AB SCIENCES (FRANCE),
- Arog Pharmaceuticals, Inc. (U.S),
- Boston Biomedical, Inc. (U.S),
- Sun Pharmaceutical Industries Limited (India),
- Pfizer Inc. (U.S),
- NATCO Pharma Limited (U.S).
The global gastrointestinal stromal tumors market is segmented on the basis of the indication, diagnosis, treatment, and end-user.
On the basis of indication, the market is classified into stomach, small intestine, large intestine (colon), and other indications.
On the basis of diagnosis, the market is segmented into imaging studies, plain abdominal radiography, barium and air (double-contrast) series, computed tomography scans of the abdomen and pelvis, magnetic resonance imaging, endoscopy, endoscopic ultrasonography, and others.
The global gastrointestinal stromal tumors market on the basis of treatment is segmented into surgery, targeted therapy, radiation therapy, chemotherapy, ablation, embolization and others. Targeted therapy is further segmented into Tyrosine kinase inhibitors (TKIs), Imatinib, Sunitinib, Regorafenib, and others. While, ablation is segmented into Radiofrequency ablation (RFA), ethanol (alcohol) ablation, microwave thermotherapy, cryosurgery (cryotherapy), and others.
On the basis of end-user, the global gastrointestinal stromal tumors market is segmented into hospitals & clinics, ambulatory surgical centers, and others.
Geographically, the market has been segmented into America, Europe, Asia Pacific, and the Middle East & Africa. The Americas gastrointestinal stromal tumors market is further segmented into North America, and South America. North America is further classified as the U.S. and Canada.
The European gastrointestinal stromal tumors market is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, the U.K., Italy, Spain, and the Rest of Western Europe.
The Asia Pacific gastrointestinal stromal tumors market is segmented into Japan, China, India, Republic of Korea, Australia, and the Rest of Asia Pacific.
The Middle East & Africa gastrointestinal stromal tumors market is segmented into the Middle East and Africa.
Regional Market Summary
Globally, the American region is the largest market for gastrointestinal stromal tumors owing to the increasing occurrence of liver cancer, the presence of major manufacturers in the region, and the development for the products. Moreover, increasing presence of genetic disorders in the U.S., robust healthcare infrastructure, availability of exclusive medical facilitates for caretaking of patients suffering from inoperable cancers will continue to drive the growth of the American gastrointestinal stromal tumor market.
Europe accounted for the second largest share in global gastrointestinal stromal tumors market in 2017. Growing number of cases of gastrointestinal stromal tumors is a major driving force of this market. Approximately 11 to 20 people per million worldwide are diagnosed with GIST each year, and in Europe, there are an estimated 15 people per million living with GIST.
Asia Pacific is expected to be the fastest growing market for gastrointestinal stromal tumors market owing to the developing healthcare facilities, increasing awareness, and changing healthcare facilities. Moreover, major companies are grabbing these opportunities and expanding their presence in the region. Furthermore, increasing research and development in this region has further enhanced the growth of the market.
The Middle East & Africa also shows a steady rise in the market owing to limited availability of medical facilities, and to the lack of knowledge in the medical sector.
Browse Complete 80 Pages Premium Research Report Enabled with 100 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/gastrointestinal-stromal-tumors-market-1583
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Phone: +1 646 845 9312